EP2515849A1 - Comprimé effervescent et formulation granulaire comprenant cefixime - Google Patents

Comprimé effervescent et formulation granulaire comprenant cefixime

Info

Publication number
EP2515849A1
EP2515849A1 EP10795486A EP10795486A EP2515849A1 EP 2515849 A1 EP2515849 A1 EP 2515849A1 EP 10795486 A EP10795486 A EP 10795486A EP 10795486 A EP10795486 A EP 10795486A EP 2515849 A1 EP2515849 A1 EP 2515849A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
composition according
cefixime
binder
effervescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10795486A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2515849A1 publication Critical patent/EP2515849A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Definitions

  • Present invention relates to tablet forms comprising cefixime. Said tablet forms are characterized by being in effervescent form.
  • Cefixime was first described in European patent no EP0030630 (Bl) and it is known with the chemical name of (6R,7R)-7- ⁇ [2-(2-amino-l,3-thiazol-4-yl)-2-
  • carboxylic acid (Formula 1). It is defined as a third generation cephalosporin and indicated for use in the treatment of infections caused by gram positive and gram negative bacteria.
  • Cefixime physically appears as white or light yellow crystal powder. It is freely soluble is methanol and propylene glycol, partially soluble in ethanol and acetone however it does not dissolve in ether, ethyl acetate, hexane and water. Its solubility in aqueous solutions changes with respect to the pH of the solution. Accordingly its solubility in a solution with a pH value of 3.2 is 0.5 mg/mL at room temperature; however when the pH of the solution is increased to 4.2 solubility increases to 18 mg/mL.
  • the product named as SUPRAX that is sold by Fujisawa/Astellas comprises cefixime as active agent and is present in oral tablet or oral suspension forms and in dosages comprising high amounts like 200 mg and 400 mg cefixime.
  • Tablets comprising 200 mg or 400 mg active agents become very big in size when formulated with excipients and this causes problems about use of these tablets for patients having difficulty in swallowing, especially for pediatric and geriatric patients.
  • Suspension forms that are developed to overcome these problems are undesirable since it is possible to take uncontrolled or high dose and in addition to that they have chemical and physical stability problems, have high manufacturing cost, and cause problems when used or when carried.
  • EP0281200 discloses fast dispersing tablets comprising microcrystalline cellulose, microfine cellulose or a mixture thereof in an amount of 24-70 %.
  • Inventors have surprisingly developed a tablet formulation that disperses in water without using cellulose based disintegrants.
  • Subject of the present invention is related to formulation of effervescent tablets and granules comprising cefixime and processes for preparation of these. Surprisingly it was found that effervescent tablets comprising cefixime, which has a low solubility, and formulated with the formulation given in the present invention dissolves in water and forms a homogenous cefixime solution.
  • first aspect of the invention is effervescent tablet and granule formulations comprising cefixime.
  • Second aspect of the invention is use of cefixime in an amount 1-60%, preferably in an amount 5-50% and more preferably in an amount 10-40% in effervescent tablet and granule formulation of the present invention.
  • Cefixime used in the invention can be in monohydrate, dihydrate, trihydrate and/or anhydrous form.
  • Another aspect of the invention is pharmaceutical composition comprising cefixime and in addition to that pharmaceutically acceptable excipients.
  • Said pharmaceutical composition is formulated for effervescent tablet and granule forms. Accordingly, another aspect of the invention relates to pharmaceutical compositions for oral application, comprising cefixime and pharmaceutically acceptable excipients such as effervescent couple, sweetener, binder, water soluble lubricant and flavoring agents and other pharmaceutically acceptable excipients.
  • cefixime and pharmaceutically acceptable excipients such as effervescent couple, sweetener, binder, water soluble lubricant and flavoring agents and other pharmaceutically acceptable excipients.
  • cefixime can be present in an amount of 1-60%
  • effervescent couple can be present in an amount of 10-90%
  • sweetener can be present in an amount of 0.1-5%
  • binder can be present in an amount of 0.1-10%
  • water soluble lubricant can be present in an amount of 0.1-5%
  • flavoring agent can be present in an amount of 0.1-5%.
  • Said effervescent couple can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid etc., basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium hydrogen carbonate etc.
  • Sweetener that can be used in the tablet and granule formulations of the present invention can be selected from a group comprising acesulfame, aspartam, fructose, maltitol, xylitol, saccharine, sodium cyclamate, sucralose, sucrose. Preferably aspartame is used.
  • Water soluble lubricant that can be used in the tablet and granule formulations of the present invention can be selected from a group comprising PEG6000 and sodium benzoate.
  • PEG6000 polyethylene glycol
  • 1-2000 mg of cefixime or its pharmaceutically acceptable salts, hydrates, solvates and/or a combination of these in an amount equivalent to 1-2000 mg cefixime can be used.
  • Binder that can be used in the tablet and granule formulations of the present invention can be selected from a group comprising; ethyl cellulose, gelatine, hypromellose, magnesium aluminium silicate, maltodextrin, polyethylene oxide and povidone.
  • the preferred binder is povidone. It was seen that in tablets in which cefixime :povidone ratio is 20:1, preferably 15:1 and most preferably 10:1 physical qualities such as friability and stability and chemical properties such as solubility and dispersibility have the desired characteristics and that the said ratio plays an important role in obtaining water soluble cefixime effervescent tablets and granules.
  • another aspect of the present invention is effervescent tablet formulations comprising cefixime and povidon in an amount such that cefixime:povidon ratio is 20:1, preferably 15:1 and more preferably 10:1.
  • Another aspect of the invention is use of the pharmaceutical compositions for the treatment of infections caused by gram positive and gram negative bacteria.
  • Another aspect of the invention is related to processes for use in the preparation of effervescent tablet and granules comprising cefixime. Said process comprises use of wet and/or dry granulation techniques present in the state of the art.
  • a process for the preparation of the effervescent tablet or granule according to the present invention comprises granulation of cefixime, effervescent couple, sweetener and binder with water or an aqueous solution, drying of the formed granules, mixing dried granules with flavoring agent and water soluble lubricant and optionally compressing the formed mixture in tablet pressing machine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La présente invention concerne des formes en comprimés comprenant cefixime, qui se caractérisent en ce qu'elles se présentent en comprimés effervescents.
EP10795486A 2009-12-25 2010-12-03 Comprimé effervescent et formulation granulaire comprenant cefixime Withdrawn EP2515849A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2009/09786A TR200909786A1 (tr) 2009-12-25 2009-12-25 Sefiksim içeren efervesan tablet ve granül formülasyonu.
PCT/TR2010/000241 WO2011078821A1 (fr) 2009-12-25 2010-12-03 Comprimé effervescent et formulation granulaire comprenant cefixime

Publications (1)

Publication Number Publication Date
EP2515849A1 true EP2515849A1 (fr) 2012-10-31

Family

ID=43532584

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10795486A Withdrawn EP2515849A1 (fr) 2009-12-25 2010-12-03 Comprimé effervescent et formulation granulaire comprenant cefixime

Country Status (3)

Country Link
EP (1) EP2515849A1 (fr)
TR (2) TR200909786A1 (fr)
WO (2) WO2011078821A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111544412A (zh) * 2020-04-17 2020-08-18 广州白云山医药集团股份有限公司白云山制药总厂 头孢克肟组合物及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962041B2 (en) 2013-02-12 2015-02-24 Johnson & Johnson Consumer Companies, Inc. Methods and compositions for enhancing hair quality using blackberry extract
CN103494821B (zh) * 2013-10-01 2018-09-25 迪沙药业集团有限公司 一种头孢克肟组合物
CN104366648A (zh) * 2014-10-21 2015-02-25 宣城柏维力生物工程有限公司 甜橙vc泡腾片
CN113440530B (zh) * 2021-07-08 2023-08-08 广州白云山医药集团股份有限公司白云山制药总厂 一种头孢克肟药物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
DE3887179T2 (de) 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
DE69712332T2 (de) 1996-02-29 2002-10-02 Fujisawa Pharmaceutical Co Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung
CN100417383C (zh) * 2006-03-07 2008-09-10 中国药科大学 一种含有头孢克肟的泡腾片及制法
CN101606913B (zh) * 2009-07-16 2012-12-19 广州白云山制药股份有限公司广州白云山制药总厂 头孢克肟分散片及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011078821A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111544412A (zh) * 2020-04-17 2020-08-18 广州白云山医药集团股份有限公司白云山制药总厂 头孢克肟组合物及其制备方法
CN111544412B (zh) * 2020-04-17 2022-06-24 广州白云山医药集团股份有限公司白云山制药总厂 头孢克肟组合物及其制备方法

Also Published As

Publication number Publication date
TR200909786A1 (tr) 2011-07-21
WO2011078832A1 (fr) 2011-06-30
TR201003856A1 (tr) 2011-08-22
WO2011078821A1 (fr) 2011-06-30

Similar Documents

Publication Publication Date Title
EP3417861B1 (fr) Composition pharmaceutique contenant un inhibiteur de janus kinase (jak) ou un sel pharmaceutiquement acceptable de celui-ci
JP5671560B2 (ja) 固体投与形中のテトラサイクリン金属錯体
US9408915B2 (en) Tolvaptan solid dispersion and its preparation method
WO2017108605A1 (fr) Composition pharmaceutique comprenant du dasatinib amorphe
MXPA02001116A (es) Dispersante solido cefuroxima axetil no cristalino, proceso para preparar el mismo y composicion para la administracion oral del mismo.
WO2011078821A1 (fr) Comprimé effervescent et formulation granulaire comprenant cefixime
JPWO2018199282A1 (ja) エンザルタミドを含有する経口投与用医薬組成物
TWI780270B (zh) 固體分散體
EP2515850B1 (fr) Compositions pharmaceutiques comprenant cefdinir comme principe
EP2568957A1 (fr) Composition pharmaceutique comprenant la céfixime et un composé dérivé de l'acide clavulanique
WO2011139249A2 (fr) Composition pharmaceutique renfermant du cefdinir
WO2011129792A1 (fr) Formulations dispersibles dans l'eau comprenant le cefpodoxime proxétil
WO2011093828A2 (fr) Formes posologiques solides comprenant du cefprozil
WO2012060786A2 (fr) Formulations de proxétil cefpodoxime comprenant un agent de viscosité
WO2012026907A2 (fr) Préparations de cefpodoxime proxétil
WO2022004859A1 (fr) Composition pharmaceutique orale et son procédé de fabrication
WO1989006959A1 (fr) Preparation pharmaceutique a liberation amelioree
WO2017037645A1 (fr) Formulations pharmaceutiques stables de tériflunomide
JP2010111630A (ja) アズレンスルホン酸塩含有粒子及びその製造方法、ならびにこれを含む医薬製剤
WO2012060787A1 (fr) Comprimés contenant du cefdinir
KR20050054993A (ko) 경구 흡수성이 개선된 항균성 약제학적 조성물
JP2021518422A (ja) レナリドミドを含む医薬組成物
US20130035344A1 (en) Pharmaceutical composition for oral administration
WO2012060791A2 (fr) Procédé de production de compositions pharmaceutiques comprenant du cefdinir
KR101577871B1 (ko) 레바미피드의 경구용 고형제제 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131116